CORDIS
EU research results

CORDIS

English EN

SLAMF7-CAR T cells prepared by Sleeping Beauty gene-transfer for immunotherapy of multiple myeloma – a rare hematologic disease

Project information

Grant agreement ID: 754658

Status

Ongoing project

  • Start date

    1 January 2018

  • End date

    30 April 2022

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 6 097 875

  • EU contribution

    € 6 097 875

Coordinated by:

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT

Germany

Objective

CARAMBA is proposing to use the revolutionary CAR-T cell technology to tackle multiple myeloma, a rare and incurable hematologic malignancy. Myeloma is associated with a substantial socioeconomic burden and there is a strong demand by patients, their families and caregivers for a curative myeloma treatment. The CARAMBA investigators will conduct a phase I/II clinical trial of immunotherapy with patient-derived T cells that are engineered to express a synthetic chimeric antigen receptor (CAR) specific for the myeloma antigen SLAMF7. SLAMF7 is uniformly expressed on all myeloma cells in every patient, and SLAMF7 CAR-T cells will be equally effective in women and men. The efficacy and safety of SLAMF7 CAR-T cells has been validated by the coordinator in comprehensive pre-clinical testing which highlighted their unprecedented curative potential. SLAMF7 CAR-T cells have received an orphan designation for the indication multiple myeloma by the EC. The successful conduct, rapid and complete recruitment into the clinical trial is ensured by participation of 4 clinical myeloma centres of excellence in 4 EU member states, and the largest myeloma patient advocacy group in Europe, MPE. The SME partners in CARAMBA are prepared to develop the SLAMF7 CAR product all the way to market authorization. CAR-T cell therapy has been recognized as a ‘Breakthrough Therapy’ and clinical proof-of-concept obtained with CD19 CAR-T cells in leukemia and lymphoma. CARAMBA is building on novel and proprietary, cutting-edge CAR technologies including virus-free Sleeping Beauty CAR gene-transfer from DNA minicircles which substantially reduces the cost of CAR-T cell manufacturing, making it an economically viable and sustainable medicinal product. We are confident, that if funded, CARAMBA will accomplish its objective to establish the role of CAR-T cell therapy as a therapeutically effective, commercially attractive and socioeconomically desirable treatment in myeloma and other rare diseases.

Coordinator

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT

Address

Josef-Schneider-Strasse 2
97080 Wurzburg

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 021 250

Participants (9)

OSPEDALE SAN RAFFAELE SRL

Italy

EU Contribution

€ 893 125

UNIVERSIDAD DE NAVARRA

Spain

EU Contribution

€ 624 375

CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE

France

EU Contribution

€ 384 375

BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL

Germany

EU Contribution

€ 342 875

DRK-BLUTSPENDEDIENST BADEN-WURTTEMBERG-HESSEN GGMBH

Germany

EU Contribution

€ 685 000

MYELOMA PATIENTS EUROPE AISBL

Belgium

EU Contribution

€ 115 625

NBE-THERAPEUTICS AG

Switzerland

EU Contribution

€ 200 000

T-CURX GMBH

Germany

EU Contribution

€ 503 750

ARTTIC

France

EU Contribution

€ 327 500

Project information

Grant agreement ID: 754658

Status

Ongoing project

  • Start date

    1 January 2018

  • End date

    30 April 2022

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 6 097 875

  • EU contribution

    € 6 097 875

Coordinated by:

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT

Germany